These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21861671)

  • 1. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
    Sistare FD; DeGeorge JJ
    Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generic operational strategy to qualify translational safety biomarkers.
    Matheis K; Laurie D; Andriamandroso C; Arber N; Badimon L; Benain X; Bendjama K; Clavier I; Colman P; Firat H; Goepfert J; Hall S; Joos T; Kraus S; Kretschmer A; Merz M; Padro T; Planatscher H; Rossi A; Schneiderhan-Marra N; Schuppe-Koistinen I; Thomann P; Vidal JM; Molac B
    Drug Discov Today; 2011 Jul; 16(13-14):600-8. PubMed ID: 21570476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety biomarker applications in drug development.
    Schomaker S; Ramaiah S; Khan N; Burkhardt J
    J Toxicol Sci; 2019; 44(4):225-235. PubMed ID: 30944276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Industry perspectives on biomarker qualification.
    Lavezzari G; Womack AW
    Clin Pharmacol Ther; 2016 Feb; 99(2):208-13. PubMed ID: 26378777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A guidance for renal biomarker lead optimization and use in translational pharmacodynamics.
    Ozer JS
    Drug Discov Today; 2010 Feb; 15(3-4):142-7. PubMed ID: 20026239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical biomarker qualification.
    Sauer JM; Porter AC;
    Exp Biol Med (Maywood); 2018 Feb; 243(3):222-227. PubMed ID: 29171289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
    Amur S; LaVange L; Zineh I; Buckman-Garner S; Woodcock J
    Clin Pharmacol Ther; 2015 Jul; 98(1):34-46. PubMed ID: 25868461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of clinical imaging in oncological drug development.
    Murphy PS; McCarthy TJ; Dzik-Jurasz AS
    Br J Radiol; 2008 Sep; 81(969):685-92. PubMed ID: 18541632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of drugs withdrawn from the market.
    Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
    Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in the drug development process: report from workshop discussions.
    van Gool AJ; Spindler P; Harpur E; Bounous D; Olejniczak K; van de Klundert FA; Haenen B
    Regul Toxicol Pharmacol; 2008 Nov; 52(2):75-6. PubMed ID: 18556099
    [No Abstract]   [Full Text] [Related]  

  • 20. The practice of pre-marketing safety assessment in drug development.
    Chuang-Stein C; Xia HA
    J Biopharm Stat; 2013; 23(1):3-25. PubMed ID: 23331218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.